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The triple-transgenic Alzheimer (3 Tg-AD) mouse expresses mutant PS1M146V, APPswe, and tauP301L transgenes and
progressively develops plaques and neuroﬁbrillary tangles with a temporal- and region-speciﬁc proﬁle that resembles the
neuropathological progression of Alzheimer’s disease (AD). In this study, we used proteomic approaches such as
two-dimensional gel electrophoresis and mass spectrometry to investigate the alterations in protein expression occurring in the
brain and cerebellum of 3 Tg-AD and presenilin-1 (PS1) knock-in mice (animals that do not develop Ab- or tau-dependent
pathology nor cognitive decline and were used as control). Finally, using the Ingenuity Pathway Analysis we evaluated novel
networks and molecular pathwaysinvolvedinthisAD model. We identiﬁed several differentiallyexpressedspotsand analysis of
3 Tg-AD brains showed a signiﬁcant downregulation of synaptic proteins that are involved in neurotransmitter synthesis,
storage and release, as well as a set of proteins that are associated with cytoskeleton assembly and energy metabolism.
Interestingly, in the cerebellum, a structure not affected by AD, we found an upregulation of proteins involved in carbohydrate
metabolism and protein catabolism. Our ﬁndings help to unravel the pathogenic brain mechanisms set in motion by mutant
amyloid precursor protein (APP) and hyperphosphorylated tau. These data also reveal cerebellar pathways that may be
important to counteract the pathogenic actions of Ab and tau, and ultimately offer novel targets for therapeutic intervention.
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Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder that leads to cognitive and behavioral impairments.
The pathological hallmarks of AD are neuritic plaques mainly
composed of the b-amyloid (Ab) peptide as well as intra-
neuronal neuroﬁbrillary tangles (NFT) made of aggregated
hyperphosphorylated microtubule-associated protein (MAP)
tau (h-tau). Extracellular amyloid plaques are formed by the
aggregation of the Ab1–40 and Ab1–42 peptides, fragments
obtained from the proteolytic cleavage of the full-length
amyloid precursor protein (APP) through the activity of the
b- and g-secretase enzymes. This process, recapitulated in
the ‘amyloid cascade hypothesis’, is thought to be the
main mechanism leading to the synaptic loss and cognitive
impairment observed in AD patients.
1 Ab peptides also
accumulate intraneuronally where they promote mito-
chondrial and proteasome dysfunction as well as calcium
dyshomeostasis, and also facilitate the hyperphosphorylation
of MAP tau thereby promoting NFT formation (reviewed in
LaFerla et al.
2). Only 1% of AD cases are familial, whereas
mostADcasesaresporadic.FamilialAD(FAD)islinkedtothe
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www.nature.com/cddispresence of autosomal dominant mutations in at least
three genes encoding the amyloid precursor protein (APP)
and the presenilins 1 and 2 (PS1 and PS2); two components
of the g-secretase complex that are located on chromosomes
21,14,and1.
3ThesemutationsleadtoanincreaseinAb1–42
production. By contrast, the link between tau protein muta-
tions and NFT formation in the AD brain is still unknown;
however, mutant P301L tau leads to its hyperphosphorylation
andNFT productioninfrontotemporal dementia aswell asina
form of parkinsonism linked to a mutation found in chromo-
some 17.
4 Thus, although not speciﬁc for AD, the P301L tau
mutation is key to model tau neuropathology in transgenic
animal models.
Recently, a triple-transgenic mouse model of AD
(3 Tg-AD; expressing mutant PS1M146V, APPswe, and
tauP301L) has been developed.
5 This mouse exhibits both
Ab and h-tau alterations, thereby recapitulating most of the
pathological features of the AD brain.
In recent years, several studies have described the
differential protein expression proﬁle in the brain of transgenic
AD models (reviewed in Sowell et al.
6) and a recent study has
analyzed protein alterations occurring in male 3 Tg-AD
mice.
7 In contrast, the cerebellar proteome in samples from
ADmiceorADpatientshasbeenlessinvestigated,mostlikely
because the prevailing assumption is that this central nervous
system (CNS) area is relatively unaffected by AD. However,
it must be noted that some studies indicate that also the AD
cerebellumshowssomesignsofmorphologicalandmetabolic
dysfunctions.
8
In this study, we performed a proteomic analysis in brains
and cerebella of 14-month-old 3 Tg-AD and control (CTRL)
presenilin-1 knock-in (PS1-KI) female mice using two-dimen-
sional gel electrophoresis (2D-E) and protein identiﬁcation
by mass spectrometry (MS). PS1-KI mice harboring the
FAD-related M146V PS1 mutation do not express mutant
APP or h-tau, do not show any AD-related cognitive decline
nor Ab- or tau-mediated pathology,
9 thereby providing an
adequate control to investigate the speciﬁc impact of the
AD-like Ab and tau pathology occurring in 3 Tg-AD mice.
Finally, using the Protein Analysis Through Evolutionary
Relationship (PANTHER) application system and Ingenuity
Pathway Analysis (IPA), we inferred the functional role and
networks linked to the proteins that we found differentially
expressed.
Results
Protein expression proﬁle and identiﬁcation of
differentially expressed proteins in the brain and
cerebellum of PS1-KI and 3 Tg-AD mice. 2D-E-based
analysis of protein expression proﬁle of brain and cerebellum
in PS1-KI (CTRL) and 3 Tg-AD mice showed that 2D-E gel
protein-spot patterns were qualitatively and quantitatively
similar across all the analyzed gels. On average, we found
300 and 200 spots per gel in the brain and cerebellum,
respectively. Of these genes, 86% (for the PS1-KI mice) and
96% (for 3 TG-AD mice) were present across the four
maps obtained from these two CNS regions. A subsequent
analysis was performed only on common spots. Statistical
analysis of the densitometry data allowed the identiﬁcation
of differentially expressed protein spots among PS1-KI
and 3 Tg-AD maps. As shown in Figure 1, we found 35
(in the whole brain) and 24 (in the cerebellum) differentially
expressed spots that reached statistical signiﬁcance
(Po0.05).
We then identiﬁed the differentially expressed proteins.
Peptide mass ﬁngerprinting (PMF) by matrix-assisted laser
desorption ionization-time of ﬂight MS (MALDI-TOF-MS)
analysis resulted in the identiﬁcation of 26 (for the whole
brain) and 14 (for the cerebellum) proteins (Tables 1 and 2).
For protein identiﬁcation, we considered only the proteins that
can be resolved by the used electrophoretic procedures. In
proteomic studies, efforts have been made to standardize
results of PMF experiments. To that aim, we calculated the hit
ratio (HR), the excess of limit-digested peptides (ELDP), the
mass coverage (MC), and the peptide mass ﬁngerprint score
(PMFscore) as quality metrics for each mass spectrum that
we have submitted for search in the database. To evaluate
the quality of protein identiﬁcation by PMF, we applied the
methodological approach proposed by Stead et al.
10 Using
a large protein data set, Stead et al. showed that a speciﬁcity
of 99% and a sensitivity of 78% in protein identiﬁcation are
accomplished when the PMFscore is higher than 79 and such
cutoff was implemented in our study. Only in the case of four
brain(spots2,9,23,and 30)andfourcerebellar (spots19,22,
23, and 24) proteins we calculated a PMFscore lower than 79.
MS/MSexperiments werethenperformedtovalidatethePMF
data. Sequences of the identiﬁed peptides, the corresponding
Mascot identiﬁcation scores, as well as the peptide scores of
PSD-MALDI-TOF-MS analysis of at least two of the most
abundant signals detected in each protein spectrum are
shown in Tables 1 and 2. In all cases, MS/MS analysis of the
selected peptides conﬁrmed the identiﬁcations obtained with
PMF experiments.
Theoretical and experimental molecular weights (MWs) as
well as isoelectric points (pIs) calculated from 2D-E maps are
shown in Tables 1 and 2. The values of MW and pI of each
protein corresponded roughly to its position on the 2D-E gel.
Deviations from theoretical MW and pI were found to be
lower than 30% in several cases. In the case of brain
spot 11, identiﬁed as Drebrin 1, we observed a signiﬁcant
deviation from its theoretical MW; this is however compatible
with its apparent MW of B130kDa in sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
as previously reported.
11 Some representative differentially
expressed proteins are shown in Figure 2a (for whole brain)
and b (for the cerebellum). The mean density ratios (n¼4)
calculated for each identiﬁed proteins are depicted in Tables 1
and 2. Out of the 26 identiﬁed brain proteins, 23 were
signiﬁcantly downregulated (Table 1).
In contrast, all the identiﬁed cerebellar proteins were
upregulated (Table 2). Interestingly, some of the cerebellar
upregulated proteins, Rho-GDP dissociation inhibitor 1
(ARHGDA), brain creatine kinase (CKB), dihydropyrimidi-
nase-like2 protein (DPYSL2), enolase 1 (a) (ENO1), gluta-
mate dehydrogenase 1 (GLUD1), isocitrate dehydrogenase 3
(NADþ) a (IDH3A), and lactate dehydrogenase B (LDHB)
were, on the contrary, signiﬁcantly downregulated in the
whole brain.
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Cell Death and DiseaseFunctional and protein network analysis. To investigate
the functional signiﬁcance of the protein differentially expres-
sed, we performed a functional classiﬁcation by using
PANTHER application system (Figure 3). In the whole brain
(Figure 3a), this analysis resulted in four clusters related to
carbohydrate metabolism, cell structure and motility, transport,
and intracellular protein trafﬁc, whereas in the cerebellum
(Figure 3b) we found two clusters related to carbohydrate
metabolism and protein metabolism and modiﬁcation. Further
analysis in the Swissprot database (www.expasy.org)
showed that six of the downregulated brain proteins, mito-
chondrial aconitase 2 (ACO2), GLUD1, mitochondrial glycerol-3-
phosphate dehydrogenase 2 (GPD2), IDH3A, oxoglutarate
dehydrogenase-like protein (OGDHL), ubiquinol-cytochrome c
reductase core protein I (UQCRC1) are localized in mitochondria
in which they function as enzymes involved in the tri-carboxylic
acid (TCA) cycle and in oxidative phosphorylation.
To obtain further insight of potential biological mechanisms
involving the differentially expressed proteins, we performed
an Ingenuity Knowledge Base search using the IPA appli-
cation. This tool builds protein networks based on known
direct and indirect interactions described in the literature
and deﬁnes common functional and canonical pathways.
The IPA-generated networks show the identiﬁed proteins
along with other interacting proteins and/or endogenous
chemicals.
A search in the Ingenuity Knowledge Base identiﬁed two
‘high score’ overlapping networks (Figures 4a and b; Supple-
mentary Table S1). These networks contain the following
16 identiﬁed proteins (focus genes): ACO2; ARHGDIA; CKB;
DBN1; dynamin 1 (DNM1); DPYSL2; GLUD1; GPD2; heat
shock protein 90kDa b (Grp94) member 1; LDHB; neuro-
ﬁlament, medium polypeptide (NEFM); phosphatidylinositol
transferprotein-a(PITPNA);synaptosomal-associatedprotein,
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Cell Death and Disease25kDa (SNAP25); synuclein-a (SNCA); triosephosphate
isomerase 1 (TPI1); and tropomyosin 1 (TPM1); and seven,
ATPase, H
þ transporting, lysosomal 70kDa, V1 subunit A
(ATP6V1A); ATPase, H
þ transporting, lysosomal 56/58kDa,
V1 subunit B2; ENO1; hemoglobin-b; IDH3A; UQCRC1; and
WD repeat domain 1 (WDR1). Two molecules, dehydro-
isoandrosterone and peroxisome proliferator-activated
receptorg-co-activator1a,were foundcommonbetweenthese
networks.
The main biological functions associated with the ﬁrst
network (score¼41) are related to lipid metabolism and
molecular transport. However, IPA classiﬁed six mapped
proteins, DNM1, SNCA, DPYSL2, NEFM, DBN1, and
SNAP25, as speciﬁcally involved in the development and
functional maintenance of the nervous system as well as in
neurodegeneration. The second network (score¼15) is
signiﬁcantly associated with tissue morphology and cell
damage or degeneration in the form of cell atrophy and
swelling. Overall, the top canonical pathways associated with
the altered protein expression found in whole 3 Tg-AD
brains were the ones related to glycolysis/gluconeogenesis,
mitochondrial metabolism, and oxidative phosphorylation.
In the case of 3 Tg-AD cerebella, we found one network
(Figure 4c; Supplementary Table S1; score¼38) containing
13 focus proteins: ARHGDIA; carbonic anhydrase II (CA2);
CKB; chaperonin-containing TCP1, subunit 5 (epsilon)
(CCT5); DPYSL2; ENO1; glyoxalase I; GLUD1; IDH3A;
LDHB; phosphoglycerate mutase 1 (brain) (PGAM1);
ubiquitin carboxyl-terminal esterase L1 (UCHL1); and valo-
sin-containing protein (VCP). This network is functionally
associated to cancer, cellular growth and proliferation, as well
as to cellular compromise.
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Figure 2 Differential protein expression in brains (a) and cerebella (b) of CTRL and 3 TG-AD mice. The picture depicts representative subsections of 2D-E images.
In each panel, bar charts show relative intensities (RI) (means±s.d.; n¼4) of protein spots obtained from CTRL and 3 Tg-AD mice. *Po0.05
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Cell Death and DiseaseDiscussion
In our study, using a classical proteomic approach based
on 2-DE and MS, we analyzed the differential protein
expression associated with the combination of mutant
PS1M146V, APPSwe, and tauP301L in the brain and cerebellum
of 14-month-old 3 Tg-AD female mice. To date, there is only
one study describing the protein expression in the brain of the
same model.
7 In this study, Martin et al. evaluated the protein
expression proﬁle in the cortex and hippocampus, but not in
the cerebellum, of 16-month-old male 3 Tg-AD mice (for a
detailed analysis of the differences between the two studies
see Supplementary Figure S1 and Supplementary Table S2).
In their study, Martin et al. proposed a gel-free proteomics
platform that, compared to what we were able to identify,
allows the identiﬁcation of a higher number of differentially
expressed proteins. However, it must be noted that although
gel-free proteomics has a higher throughput and overcomes
some limitations of gel-based proteomics (such as the poor
separation of highly hydrophobic proteins or proteins showing
extreme, low or high, pI values, and MW), 2D-E is currently
considered the standard technique for studying the relative
quantiﬁcation of protein variants. In that respect, our ﬁndings
are not merely reproducing what already described by Martin
et al., but are novel and complementary to such data set.
Furthermore, Martin et al. chose to analyze selected brain
subregions such as the hippocampus and the cortex to
provide insightful information on the regional progression of
the AD-like pathology in 3 Tg-AD mice. However, it should
be noted that the 3 Tg-AD mice do not show a clear
reproducible speciﬁc regional pattern of amyloid deposition
and tau pathology.
12 Thus, to avoid a great deal of variability,
we have chosen to analyze proteomic change in the whole
brain.
Finally, it must be also emphasized that gender has a
signiﬁcant impact on the cognitive and neuropathological
phenotype of AD model
13 with female 3 Tg-AD mice
exhibiting a more aggressive disease progression.
12 We
therefore decided to investigate the whole brain and cere-
bellum of female 3 Tg-AD mice at 14 months of age (m.o.a.)
as 3 Tg-AD mice show intraneuronal Ab accumulation
at 3–4m.o.a., amyloid plaques at 12m.o.a. whereas they
do develop NFTs at 12–15m.o.a.
14 We would also like to
emphasize that, to date, this is the ﬁrst study describing
cerebellar proteomic changes of 3 Tg-AD mice. Cerebellum
is less affected than other CNS areas from AD and our data
can therefore provide critical information on region-speciﬁc
mechanisms that are counteracting the development
of AD-related injury. Finally, we chose to investigate age-
matched female PS1-KI mice as CTRL model because
mutant PS1 mice show elevated levels of murine Ab as well
as dyshomeostasis of intracellular Ca
2þ,
15 but do not exhibit
any Ab- or tau-dependent neuronal degeneration or cognitive
impairment.
9 In fact, given the amino-acid composition of
murine amyloid as well as the different susceptibility of murine
APP to the enzymatic cleavage by BACE1, the peptide is
unable to aggregate to form plaques or intracellular deposits.
Therefore, the mere expression of mutant PS1 has no effects
on parenchymal or intraneuronal amyloid deposition,
16,17 and
it is only when human mutant PS1 is co-expressed along with
human mutant APP that amyloid-driven overload and patho-
logy can be observed and studied in murine AD models.
17
Overall,ourdataareofteninagreementwiththeexpression
levels of several proteins found in brains of AD patients and/or
AD animal models.
6,18
To further elucidate the functional implications of the
changes we detected, we plot the data into canonical
pathways assuggestedbythe PANTHER application system.
This analysis indicates that the proteins we found to be
differentially expressed in the whole brain are functionally
organized in at least four clusters, namely carbohydrate
metabolism, cell structure and motility, transport, and intra-
cellular protein trafﬁc (Figure 4a).
Impairment of brain metabolism has been recognized as a
hallmark of AD and the reduction of glucose utilization is
paralleled by a decrease in the expression of glycolytic
enzymes.
19
In our study, we observed a signiﬁcant downregulation of
proteins such as TPI1 and ENO1, which could explain an
impaired glucose metabolism, similarly to what reported in AD
patients. Our analysis also reveals the downregulation of
mitochondrialproteinslikeFAD-dependentGDP2,ACO2,two
isoforms of the a subunit of NAD
þ-dependent isocitrate
dehydrogenase complex (IDH3A), as well as OGDHL, a
brain-speciﬁc isoenzyme of 2-oxoglutarate dehydrogenase
(OGDH). ACO2, IDH3, and OGDH are also key enzymes in
the TCA cycle. IDH3 activity regulates OGDH that is the
Carbohydrate metabolism
Cell structure and motility
Transport
Intracellular protein traffic
Other metabolism
7; 29.2%; 17.5%
5; 20.8%;
12.5%
5; 20.8%; 12.5%
20; 83.3%; 45%
3; 12.5%; 7.5%
Carbohydrate metabolism Protein metabolism and modification
Other metabolism
9; 69.2%; 56.3%
4; 30.8%; 25%
3; 23.1%; 18.8%
Figure 3 Functional classiﬁcation of identiﬁed proteins in brains (a) and
cerebella (b)o f3 Tg-AD mice. Pie charts show PANTHER classiﬁcations made
according to the biological functions associated to each protein. Numbers indicate
the number of proteins belonging to the speciﬁed functional category, the
percentage of protein hit against the total number of proteins, as well as the
percentage of protein hit against the total number of processed hits
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Cell Death and Diseaseprimary site of control of the metabolic ﬂux through the TCA
cycle. Decreased IDH and OGDH activities and expression
levels have been observed in AD brains.
20 It is interestingly to
note thatthe downregulation ofboth OGDH and mitochondrial
GLUD1, key enzymes participating in glutamate (Glu)
metabolism, can result in deranged Glu production of and
the impairment of glutamatergic neurotransmission. Further-
more,CKBwassigniﬁcantlydownregulatedinagreementwith
what reported in AD brains.
21 This downregulation might
resultindecreasedextra-mitochondrialproductionofATPand
its altered distribution to speciﬁc intracellular compartments.
Taken together, these ﬁndings suggest that Ab pathology
and tau pathology promote a signiﬁcant impairment of energy
metabolism in brains of female 3 Tg-AD mice. Our results
pinpoint the TCA cycle and mitochondrial dysfunctions as key
targets of the AD-like pathology of these mice. Gender might
have a role here as several of these proteins were not found
differentially expressed in 16-month-old male 3 Tg-AD mice
(Supplementary Table 2).
Interestingly, several evidences indicate that mitochondrial
dysfunction can greatly affect synapse functioning (reviewed
in Reddy and Beal
22).
A more direct link to altered synaptic activities is also
suggested by what we found as far as the downregulation
of proteins that have a key role in synaptic functioning
and synapse formation (DBN1, DPYSL2, SNAP25) as well as
in endocytosis and synaptic vesicle recycling (ATP6V1A,
DYN1, PITPNA). DBN1 modulates synaptic plasticity and the
Figure 4 Ingenuity Pathway Analysis of differentially expressed proteins: network interaction for brain (a and b) and cerebellar (c) proteins. Diagrams show focus genes
(theidentiﬁedproteinsfounddifferentiallyexpressed)thataredepictedingreen(downregulated)orred(upregulated).Solidanddashedconnectinglinesindicatethepresence
of direct and indirect interactions, respectively. Modulatory roles of proteins and/or endogenous chemicals on the expression of other proteins are indicated by arrows
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Cell Death and Diseaseshaping of the cytoskeleton by interacting with actin, thereby
regulating the morphogenesis, patterning, as well as the
maintenance of dendritic spines in neurons whereas DPYSL2
downregulation might be associated to neuronal and synaptic
loss as the protein is involved in axon guidance and growth,
neuritedevelopment, andneuronal polarization. Furthermore,
decreased DYN1 and PITPNA expression leads to the
impairment of synaptic release of neurotransmitters. It is
interesting to note that the downregulation of DYN1, DBN1,
DPYSL2, and SNAP25 has been reported in brains of AD
patients.
21,23–25 Synaptic loss is the major neurobiological
substrateofcognitivedysfunctioninAD
26and,takentogether,
our results suggest a signiﬁcant impairment of synaptic
functions and plasticity in the late stage AD-like pathology
observed in 3 Tg-AD mice.
Loss of functional synapses in AD also appears to be
related to amyloid- and tau-driven cytoskeleton alterations.
27
Interestingly, our results indicate that several components of
theneuronalcytoskeleton,suchasTPM1,NEFM,andWDR1,
are signiﬁcantly downregulated in the 3 Tg-AD mice.
ARHGDIA is indirectly related to the rearrangement of the
cytoskeleton. In fact, ARHGDIA inhibits Rho GTP-ase and its
main effectors serine/threonine Rho kinases that promote the
development of the growth cone and rearrange the
cytoskeleton.
28 The decreased expression of ARHGDIA
might be related to an increase of Rho GTP-ase and Rho-
kinase activities followed by an inhibition of neurite outgrowth.
Cytoskeletal alterations found in AD patients have been also
linked to deranged chaperone functions and protein misfold-
ing. The chaperon protein Hsp90 has a pivotal role in aberrant
tau degradation and/or tau refolding.
29 It is still unclear
whether tau pathology results from toxic effects of abnormally
phosphorylated MAP tau or loss of its physiological function in
AD. Possible explanations could arise by understanding the
relationship between Hsp90 and MAP tau processing.
Interestingly, insiliconetwork analysisfurther substantiates
the idea that APP and Ab modulate the expression of several
identiﬁed synaptic and cytoskeletal proteins (Figure 4a),
suggesting a key role of APP aberrant processing in the
observed proteomics alterations. For example, Ab promotes
a signiﬁcant downregulation of DBN1
30 and DYN1
31 in
cell cultures whereas intracellular levels of APP intracellular
domain have been associated to deranged function of
DPYSL2.
32 In summary, all these changes offer novel
mechanisms to further understand the synaptic toxicity of Ab.
In contrast to what is observed in the brain, all the proteins
found differentially expressed in the cerebellum resulted
to be upregulated whereas seven of these were actually
downregulated in whole brain samples (i.e., ARHGDA, CKB,
DPYSL2, ENO1, GLUD1, IDH3A, and LDHB). These results
suggest that mutant APP and/or tau affect similar pathways in
brain and cerebellum but in opposite direction. Only few data
are currently available on proteome of the cerebellum of AD
patientsorADmousemodels.Thecerebellumisthoughttobe
less affected than the cerebral cortex and hippocampus by
AD; however, pathological cerebellar changes are found in
advanced stages of AD.
8
Functional analysis of overexpressed cerebellar proteins in
3 Tg-AD mice indicates two main protein clusters related to
protein processing and carbohydrate metabolism (Figure 3b).
Among the proteins associated with protein metabolism,
we found VCP, UCHL1, and mKIAA0098 protein, also known
as CCT5. All these proteins are involved in the chaperone–
proteasome system and have been linked to AD neuro-
degeneration.
33 Increased VCP expression levels or activity
may enhance the protein degradation mediated by the
ubiquitin–proteasome system (UPS) whereas the main
function of UCHL1, an important component of the UPS,
pertains the recycling of monoubiquitin and its stabilization.
Interestingly, UCHL1 has been found to be decreased and
its level is inversely proportional to the number of NFTs in AD
brain.
34 UCHL1 is also required for normal synaptic function
and rescues Ab-related synaptic dysfunction in transgenic
AD mice.
35 CCT has been found signiﬁcantly reduced in AD
brains
36 and may be involved in AD-related cytoskeletal
abnormalities, thus it is intriguing to hypothesize that the
cerebellar upregulation we ﬁnd in 3 Tg-AD may serve a role
in counteracting these cytoskeletal alterations. This hypo-
thesis is further supported by the increased expression levels
of ARGDHA and DPYSL2. As discussed above, these
proteins have a key role in the maintenance of the neuronal
cytoskeleton and promotion of neuronal development.
Interestingly, ARHGDIA also possesses antiapoptotic
activity
37 and, thus, increased ARHGDIA levels might exert
an important neuroprotective effect on the cerebellum.
GLYO1andCA2werealsofoundspeciﬁcallyupregulatedin
the cerebellum. GLYO1 is one of the components of the
glyoxalase system that detoxiﬁes a-ketoaldehydes, prevent-
ing the formation of advanced glycation end products that
areknowntogenerateoxidativestressandreduceproteolysis
of carbonylated MAP-tau. CA2 is a CA isozyme and
decreased brain CA levels have been associated with the
alteration of synaptic spines and dendrite loss observed
during aging and AD.
38
It is again intriguing to speculate that the cerebellar
overexpression of CKB, IDH3A, LDHB, and PGAM1 as well
as mitochondrial proteins such as IDH3A and GLUD1 might
compensate for an AD-related deﬁcit of energy metabolism
that could otherwise develop in this region.
Overall, our results suggest that the cerebellum largely
differs from brain in response to the pro-AD environment
present in the 3 Tg-AD mice. Network analysis by IPA
(Figure 4c) shows networks associated with cellular growth
and proliferation. Key nodes of such networks are the MYC
oncogene and the hepatocyte growth factor, a protein that
stimulates cell proliferation. The identiﬁed network indicates
an important inhibitory effect of ARHGDIA on RHOA and
ROCK2 andalso includes actinand ubiquitin, suggesting that,
in response to pro-AD factors, the cerebellum sets in motion a
reorganization of the cytoskeleton and enhances clearance of
misfolded proteins by activating the UPS.
In conclusion, our proteomic study in the brain and
cerebellum of 3 Tg-AD mice show an interesting divergence
of effects between these two CNS regions. In the brain, we
observeasigniﬁcantdownregulationofsynaptic,cytoskeletal,
and mitochondrial proteins suggesting that synaptic and
mitochondrial dysfunction are having a key role in the
late stage of the AD-like pathology of this region. In contrast,
in the cerebellum, we ﬁnd an upregulation of proteins that
are involved in energy metabolism, clearance of misfolded
Proteomics of brain and cerebellum of 3 Tg-AD mice
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Cell Death and Diseaseprotein, and detoxiﬁcation. These ﬁndings are particularly
intriguing as they can shed new light on endogenous
mechanisms promoted by the cerebellum to counteract the
pathogenic actions of Ab and P-tau and ultimately offer novel
targets for therapeutic intervention.
Materials and Methods
Animals. Female, 14-month-old PS1-KI (CTRL, n¼4) and 3 Tg-AD (n¼4)
mice were kept in a temperature-controlled room at 251C under a 12-h light/dark
cycle and fed ad libitum with a commercial pelleted feed and water.
At the age of 14 months, mice were anesthetized and killed by decapitation.
Whole brains and cerebella were excised, weighed, immediately frozen in liquid
nitrogen, and then stored at  801C for later processing.
Allexperimentswereperformedin accordancewithgeneral guidelinesregarding
animal experiments and approved by our institutional committee for animal care.
Proteinextraction,samplepreparation, andtwo-dimensionalgel
electrophoresis. 2D-E was performed with little modiﬁcation of previous
protocols.
39 In brief, frozen brain/cerebellum tissue (at least 40mg) was
homogenized in 1ml of 8.3M urea, 2M thiourea, 2% 3-((3-cholamidopropyl)
dimethylammonio)-1-propanesulfonate hydrate, 1% dithiothreitol (DTT; Sigma-
Aldrich, Schnelldorf, Germany), 2% IPG buffer (pH 3–10), using a polytron. Crude
extracts were vigorously shaken for 30min at 41C, followed by a 30min
centrifugation at 10000 g. Determination of protein concentration was performed
using the Bio-Rad DC method (Bio-Rad Laboratories, Hercules, CA, USA). Total
protein extracts were prepared for each animal and each individual sample was
assessed separately. Samples of 250mg protein were applied to immobilized
(pH 3–10) nonlinear gradient strips (11cm; Bio-Rad Laboratories). For each
sample, triplicate runs were performed as independent experiments. Samples of
1mg protein were used for preparative gels (immobilized pH 3–10 nonlinear
gradient strips, 17cm). Focusing started at 200V, with the voltage being gradually
increased to 3500V and then kept constant for a further 66500V (PROTEAN IEF
System; Bio-Rad Laboratories). Before SDS-PAGE, the IPG strips were incubated
for 15min with a solution of Tris-Cl buffer (pH 8.8), urea (6M), glycerol (30%, v/v;
Sigma-Aldrich), SDS (2%, w/v; Sigma-Aldrich), and DTT (1%, w/v). Strips were
then equilibrated for further 15min in the same buffer containing iodoacetamide
(IAA, 5%, w/v; Sigma-Aldrich) instead of DTT. The second-dimensional separation
was performed in 12% SDS-polyacrylamide gels. After protein ﬁxation (in 40%
methanol, 7% acetic acid aqueous solution), gels were stained with colloidal
Coomassie blue (Sigma-Aldrich).
Protein visualization and image analysis. Electronic images of gels
were acquired by a calibrated densitometer (GS-800; Bio-Rad Laboratories) and
analyzed using PDQuest software (Bio-Rad Laboratories). Molecular masses were
determinedbyrunningstandardproteinmarkers,coveringtherangeof10–200kDa.
The pI values used were those given by the supplier of the IPG strips. Background
was automatically removed by the software on the basis of selected faint spots
manually identiﬁed on the master gel.
Statistical analysis. The relative intensity (RI) for each spot corresponding
to normalized values was calculated accordingly with the following formula:
RI ¼ Vi=
P n
i¼1
Viwhere Vi is the volume of the individual spot, n the number
of detected spots, and
P n
i¼1
Vi the sum of the volumes of all the matched spots.
Foreachmatchsetanalysis,mapscorrespondingto proteinextractsfromanimalsin
thesameexperimentalgroupwereorganizedinto‘ReplicateGroups’andnamedas
either (CTRL) or (3 Tg). This allowed us to carry out an automatic statistical
analysis of densitometric data, expressed as normalized spot densities by using the
Student’s t-test. Statistical signiﬁcance for differentially expressed spots was
assumed with P-values lower than 0.05. The mean density ratios of differentially
expressed proteins were then calculated.
In-gel digestion and MALDI-TOF-MS analysis. Protein spots showing
signiﬁcant changes in mean volume were selected for spot picking, trypsin
digestion, and MALDI-TOF-MS analysis. Selected protein spots were manually
excised and stored at  801C until digestion. Gel plugs were washed twice
with water and 50% acetonitrile. The cysteine residues were reduced by adding
50ml DTT (20mmoll
 1; Sigma-Aldrich) at 571C and alkylated by 50ml IAA
(100mmoll
 1; Sigma-Aldrich) at room temperature. The gel slices washed three
times for 10min each with 200ml of 40mmoll
 1 ammonium bicarbonate in 50%
acetonitrile, dehydrated with 100% acetonitrile, and then rehydrated with 20mlo fa
10mgl
 1 trypsin (Sigma-Aldrich) solution in 50mmoll
 1 ammonium bicarbonate.
Trypsin digestion was carried out at 371C for 12h. In-gel digested protein samples
were concentrated and desalted by using ZipTip C18 (Millipore, Watford,
Hertfordshire, UK) accordingly to the manufacturer’s directions. Elution was
performed with a saturated solution of a-cyano-4-hydroxycinnamic acid (50%
acetonitrile/water; Sigma-Aldrich) directly on an MTP Ground Steel 384 target
(Bruker Daltonics, Bremen, Germany). Mass spectra were acquired between 700
and 4000Da on a MALDI-TOF mass spectrometer Reﬂex IV (Bruker Daltonics)
operating in reﬂectron mode. A 50pmolml
 1 solution of angiotensin I (m/z 1296.68;
Sigma-Aldrich), ACTH (fragment 18–39, m/z 2465.19; Sigma-Aldrich), bradikynin
(fragment 1–9, m/z 1060.57; Sigma-Aldrich), and renin substrate (m/z 1758.93;
Sigma-Aldrich) was used for the external calibration. Mass spectra were processed
togeneratepeaklistsusingFlexAnalysisversion2.0(BrukerDaltonics).Automated
peak detection was performed using the SNAP algorithm and a signal-to-noise
threshold of 6. Internal calibration was based on trypsin autodigestion peptides.
Databasesearchwas performedby the Mascotalgorithm.The databasessearched
were NCBInr using the following input parameters: taxonomy¼mus musculus;
enzyme¼trypsin; allowed missed cleavages¼1; ﬁxed modiﬁcation¼
carbamidomethyl (Cys); variable modiﬁcation¼oxidation (Met); peptide
tolerance¼50 ppm; mass value¼MH
þ, monoisotopic. For each spectrum,
the HR, the ELDP, and the MC were calculated as previously reported
10 as:
HR¼(nmasses matched)/(nmasses submitted); ELPD¼(nmatched peptides having no missed cleavages) 
(nmatched peptides containing a missed cleavage site); MC¼(%sequence coverage/100) 
MW(kDa). A PMFscore was calculated from these quality metrics as: PMFscore¼
(HR 100)þMCþ(ELPD 10).
Postsourcedecay(PSD)MALDI-TOF-MS/MSspectraofatleasttwomostabundant
ions present in PMF spectra of proteins with a PMFscore lower than 79 were acquired.
MS/MS spectra were acquired by using the same MALDI-TOF mass spectrometer and
the acquisition program FAST. Twelve fragment spectra were added to obtain each
MS/MS spectrum and at least 300 shots were added for each fragment. The individual
spectra were pasted together using the Bruker FAST software. Searches in the NCBInr
or Swissprot databases were performed using the Mascot algorithm. Parent ion and
fragment mass tolerances were of 50p.p.m. and 1Da, respectively.
Functional classiﬁcation and protein network analysis. Functional
classiﬁcation of the identiﬁed proteins was performed using the PANTHER
application system
40 (http://www.pantherdb.org) that uses information on protein
sequence to assign a gene to an ontology group on the basis of the Gene Ontology
terms (http://www.geneontology.org).
In silico protein network analysis was instead performed using the IPA
application (Ingenuity System, http://www.ingenuity.com). IPA constructs hypo-
thetical protein interaction clusters on the basis of the Ingenuity Pathways
Knowledge Base. A data set containing the protein identiﬁers of the proteins found
changedandthecorrespondingexpressionvaluewasuploadedintotheapplication.
The expression values were the mean density ratios calculated for each spots. IPA
automatically converts the mean density ratios to fold changes. Direct and indirect
relationships between the identiﬁed proteins were shown as networks on the base
of all genes and endogenous chemicals present in the Ingenuity Knowledge Base.
IPA computes a score for each identiﬁed network. These scores are derived from a
P-value and indicate the likelihood that focus genes (i.e., the identiﬁed proteins
within a speciﬁc network) are clustered together. Biological functions and canonical
pathways overrepresented among the identiﬁed proteins were also assigned to
networks stored in the Ingenuity Pathways Knowledge Base. Biological functions
and canonical pathways were ranked in accordance to their signiﬁcance within
thesenetworks.SigniﬁcancewasevaluatedbyexactFisher’stest.AP-valueof0.01
corresponding to a score of 2 was considered the cutoff for the analysis.
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